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Abstract
Background: Signs and symptoms of a rapidly enlarging breast mass are not only important for all clinicians to
recognize and assess, but also are not uncommon occurrences. We describe a similar but unique case that developed
into an enormous, 36 cm exophytic mass.
Case presentation: A 51-year-old woman with history of psychiatric conditions presented for signs and symptoms
of sepsis. It was determined that the source was an enormous 36 cm mass originating from the breast/chest wall. After
stabilizing the patient with antibiotics, she underwent successful resection. Surgical margins were positive, and
histopathology demonstrated bland spindle cells with stromal overgrowth. Together with clinical and histopathological
information, the patient was diagnosed with a phyllodes tumor.
Conclusion: Differential diagnosis of rapidly growing breast masses is discussed, which are not uncommon
occurrences in clinical medicine. One etiology, phyllodes tumors, can grow into large, exophytic masses as described.
Oncologic treatment is discussed, usually consisting of surgery with postoperative radiotherapy for high-risk features.
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Background
The differential diagnosis of a rapidly growing breast mass
is very important for not only oncologists, but any health
care provider, owing to the relative ubiquity of the symp-
toms and need for further workup and treatment. In this
report, we describe the exceptional case of a woman who
noticed a rapidly growing breast mass that became ex-
tremely large. We discuss the difficulties of diagnosis as
well as differential diagnoses of which clinicians should be
aware.
Case presentation
A 51-year-old woman with history of multiple psychiatric
conditions including uncontrolled anxiety and depression
presented to the intensive care unit with tachycardia and
hypotension. She had initially felt a left breast mass five
years ago but not sought medical attention, and the mass
continued growing. Over the past sixteen weeks, the mass
had nearly tripled in size and started oozing purulent fluid.
Visual inspection revealed a 36 cm mass composed of
several different colored, shaped, and textured tissues. Fluid
drainage and necrotic debris was present (Fig. 1a) without
axillary lymphadenopathy or other pertinent physical exam-
ination findings other than appearing ill with mental obtun-
dation. She received fluid boluses and vasopressors. With
further workup including elevated lactic acid level and
white blood cell count of 31.6 thousand cells per microliter,
broad-spectrum antibiotics were commenced. Computed
tomography (CT) revealed a large, 36 cm exophytic mass
in the left chest wall/breast with homogeneous density
(Fig. 1b). Systemic staging using CT was negative.
After stability in clinical status was achieved, due to great
concern of ongoing sepsis from the necrotic/infected
tumor, emergent resection was done. Thus, pre-surgical
biopsy could not be performed, although differential diag-
noses included abscess/necrosis, sarcoma, phyllodes tumor,
and fibroadenoma. Radical mastectomy was performed
owing to intraoperative tumor involvement of the pectoralis
and intercostal muscles. Owing to the emergent circum-
stances, large tumor size with necrosis, and no prior tissue
diagnosis, nodal sampling was performed; lymph nodes
were grossly nonenlarged. Owing to no clinical nodal
disease as well as clinical suspicion for the aforemen-
tioned diagnoses, there was no indication for complete
axillary dissection. Postoperatively a clean base was
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present (Fig. 1c) with skin grafted for wound closure
aided by pressure dressings. The mass was sent for
histological analysis.
Pathological diagnosis of the mass was difficult. There
was significant (over 50 %) necrosis with bland spindle
cells being the only detectable cells (Fig. 2a). There was
only one glandular/epithelial component seen (Fig. 2b) with
significant stromal changes and high amounts of mitotic
cells (45 mitoses per 10 high-powered fields). The deep
margin of the tumor was positive as well. Pathological ana-
lysis demonstrated negative markers for neurofibroma, epi-
thelial (including breast) carcinomas, melanoma,
rhabdomyosarcoma, fibrosarcoma, or synovial sarcoma.
Whereas the pathological diagnosis was initially an un-
specified spindle cell neoplasm, adding together the clin-
ical history and presentation, the patient was diagnosed
with a phyllodes tumor.
Conclusions
Phyllodes tumors most often arise in patients in the 5th dec-
ade of life and vastly more commonly in females [1]. They
clinically present as a rapidly growing mass based in the
breast, which is an important clue for diagnosis even if
pathological diagnosis is inconclusive [2]. Spindle cellularity
rules out fat necrosis and inflammatory breast carcinoma.
Though only one epithelial (glandular) component was
seen, the complete absence of such is less common in phyl-
lodes tumors; likely, mesenchymal components of the
tumor can overgrow the glanduloepithelial components,
making the latter rare to find [1]. Phyllodes tumors are
Fig. 1 Gross appearance of the mass at presentation (a, left panel),
computed tomography image without contrast of patient at
presentation showing large exophytic mass (b, center panel), and
postoperative appearance (c, right panel)
Fig. 2 20x magnification of the resection specimen showing a
cellular malignant spindle cell tumor with nuclear atypia but without
evidence of differentiation (a, left panel), and 40x photomicrograph
showing a rare benign gland in the midst of the malignant spindle
cell tumor (b, right panel)
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often confused with soft tissue sarcomas as well, including
fibrosarcoma, which can complicate diagnosis. However,
phyllodes tumors are vastly more common than primary
breast sarcomas, occurring around 5–10 times more com-
monly, and 20–40 times more than primary breast fibro-
sarcomas [3]. Much of this involves placement of
formerly-classified fibroadenomas into other categories,
such as synovial sarcomas. Based on the WHO classifica-
tion [4], this tumor was a malignant phyllodes tumor
owing to high hypercellularity/pleomorphism, mitotic rate,
invasive margins, and stromal overgrowth.
This patient was treated with postoperative radiother-
apy, in part due to positive surgical margins, malignant
phenotype, and stromal overgrowth. A large retrospect-
ive study of 478 patients with malignant phyllodes
tumors demonstrated that tumors over 10 cm have
recurrence rates of 15 % after mastectomy and worse
survival, which was a primary consideration in proceed-
ing with radiotherapy [5]. Moreover, if a positive surgical
margin exists, it is known that stromal overgrowth in
the tumor predicts for local recurrence (LR) [6] and dis-
tant failure (DF) [7], leading some to theorize that these
patients may need systemic therapy as well, although
this issue remains unresolved.
These are in contrast to the NCCN guidelines [8],
which do not advocate radiotherapy or axillary sta-
ging, but the guidelines assume that a biopsy is per-
formed to cement the diagnosis and do not account
for emergent cases. The guidelines admit that the
subtype of phyllodes tumor is less important than
surgical margins, which has been corroborated by
other studies to predict for poorer outcomes [6, 7].
Furthermore, large cohorts analyzed through the
SEER database [9], which showed 15-year cancer-
specific survivals (CSS) of 89 %, did not demonstrate
radiotherapy to improve CSS, but due to lack of in-
formation could not assess radiotherapy’s effects on
LR, especially with positive margins. On the other
hand, a study from Europe [10] with 443 women
demonstrated 17 % of patients with LR and 3.4 %
with DF, most commonly to the lung. On multivariate
analysis, factors associated with LR included residual
disease/positive margins, borderline/malignant hist-
ology, and lack of radiotherapy. When specifically
examining malignant/borderline tumors, radiotherapy
use was associated with decreased LR. Factors associ-
ated with improved overall survival were tumors <
3 cm and absence of necrosis; for malignant tumors,
use of mastectomy instead of breast-conservation was
associated with improved overall survival. The latter
finding conflicts with aforementioned data [9], but
underscores the controversy in several aspects of
treatment, especially in the rarer cases such as this
patient.
This patient completed radiotherapy without wound
healing complications but owing to psychiatric condi-
tions and past issues of self-neglect, has failed to follow
up.
Consent
Written consent to participate and publish this case was
obtained from the patient and is available on request.
This case report was not required to be reviewed by the
Institutional Review Board committee at the University
of Nebraska Medical Center.
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